Literature DB >> 2310101

Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings.

H D Tazelaar1, R W Viggiano, J Pickersgill, T V Colby.   

Abstract

Open lung biopsies from 14 patients and autopsy tissue from one patient with polymyositis/dermatomyositis were reviewed in an attempt to correlate histologic features with clinical, radiographic, and prognostic variables. Three major groups based on histologic patterns were identified: bronchiolitis obliterans organizing pneumonia (BOOP), usual interstitial pneumonia (UIP), and diffuse alveolar damage (DAD). Patients with BOOP had a more favorable prognosis than did patients with UIP. Patients with DAD had a uniformly poor prognosis. One patient had a cellular interstitial pneumonia and did well. Histologic subclassification of the interstitial lung disease proved to be a better predictor of survival than did the radiographic appearance or the clinical presentation. These findings suggest that there is a broader range of histologic findings in polymyositis-dermatomyositis than is suggested in the literature and subclassification may be useful for prognosis.

Entities:  

Mesh:

Year:  1990        PMID: 2310101     DOI: 10.1164/ajrccm/141.3.727

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  39 in total

Review 1.  Organising pneumonia.

Authors:  J F Cordier
Journal:  Thorax       Date:  2000-04       Impact factor: 9.139

Review 2.  Imaging of the pulmonary manifestations of systemic disease.

Authors:  A G Rockall; D Rickards; P J Shaw
Journal:  Postgrad Med J       Date:  2001-10       Impact factor: 2.401

Review 3.  Polymyositis/dermatomyositis: the current position.

Authors:  A Urbano-Márquez; J Casademont; J M Grau
Journal:  Ann Rheum Dis       Date:  1991-03       Impact factor: 19.103

Review 4.  [Pulmonary manifestations in rheumatic systemic diseases].

Authors:  T Schlossbauer; C Becker-Gaab; R Eibel
Journal:  Radiologe       Date:  2005-07       Impact factor: 0.635

5.  Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.

Authors:  Julio A Huapaya; Leann Silhan; Iago Pinal-Fernandez; Maria Casal-Dominguez; Cheilonda Johnson; Jemima Albayda; Julie J Paik; Abanti Sanyal; Andrew L Mammen; Lisa Christopher-Stine; Sonye K Danoff
Journal:  Chest       Date:  2019-06-22       Impact factor: 9.410

6.  BOOP and COP.

Authors:  D M Geddes
Journal:  Thorax       Date:  1991-08       Impact factor: 9.139

7.  Inflammatory muscle disease assessment.

Authors:  Tim Y-T Lu; Kristine P Ng; David A Isenberg
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

8.  Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis.

Authors:  Eishi Miyazaki; Masaru Ando; Tomoko Muramatsu; Tetsujiro Fukami; Osamu Matsuno; Shin-Ichi Nureki; Takuya Ueno; Tomiyasu Tsuda; Toshihide Kumamoto
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

9.  Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease.

Authors:  Thomas J Richards; Aaron Eggebeen; Kevin Gibson; Samuel Yousem; Carl Fuhrman; Bernadette R Gochuico; Noreen Fertig; Chester V Oddis; Naftali Kaminski; Ivan O Rosas; Dana P Ascherman
Journal:  Arthritis Rheum       Date:  2009-07

10.  Diffuse interstitial lung disease: overlaps and uncertainties.

Authors:  Simon L F Walsh; David M Hansell
Journal:  Eur Radiol       Date:  2010-03-04       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.